Differential Impact of Cognitive Impairment in MCI Patients: A Case-Based Report

Valentina Pergher1,2, Birgitte Schoenmakers3, Philippe Demaerel4

  • 1Department of Cognitive Neuropsychology, Harvard University, Cambridge, Massachusetts, USA.

Insights

Mild cognitive impairment (MCI) involves changes in brain volume and executive functions. This study found increased white matter volume in MCI patients, offering insights into disease mechanisms.

Area of Science:

  • Neuroscience
  • Gerontology
  • Medical Imaging

Background:

  • Mild cognitive impairment (MCI) is a transitional stage between normal aging and Alzheimer's disease.
  • Existing research indicates grey and white matter volume alterations and executive function deficits in MCI.
  • The precise relationship between cognitive performance and brain volume in MCI remains incompletely understood.

Observation:

  • This study examined three individual cases of MCI using MRI scans and cognitive assessments.
  • Age-matched healthy older adults were included as controls for comparison of brain volumes and cognitive outcomes.
  • The investigation focused on the interplay between cognitive function, grey matter, and white matter volumes.

Findings:

  • Cognitive impairment significantly impacts both cognitive test performance and brain volumes (grey and white matter).
  • Cognitive and brain reserve appear to play a role in mitigating cognitive decline associated with MCI.
  • Notably, all three MCI patients exhibited increased white matter volume compared to healthy controls, a finding that warrants further investigation.

Implications:

  • The observed increase in white matter volume in MCI patients provides novel evidence for pathological mechanisms.
  • Understanding these mechanisms can enhance diagnostic approaches and therapeutic strategies for MCI.
  • This research contributes to a deeper comprehension of MCI, potentially aiding in early detection and intervention for Alzheimer's disease.
  • Further research into white matter volume changes could refine our understanding of cognitive reserve and resilience.

Related Concept Videos

Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
626
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
414
The Influence of Affect on Cognition01:29

The Influence of Affect on Cognition

Positive affect significantly influences cognitive processes, including evaluation, memory, creativity, and social judgments. Compared to negative affect, positive emotional states promote more favorable interpretations of stimuli, cognitive flexibility, and heuristic processing. These effects highlight emotions' powerful role in shaping how individuals perceive, remember, and interact with the world.Influence on Evaluation and AttributionWhen individuals experience positive affect, they are...
204
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
425
Methods of Documentation VI: Case Management Model01:15

Methods of Documentation VI: Case Management Model

The case management model is a multidisciplinary approach that involves healthcare professionals from diverse disciplines, such as physicians, nurses, therapists, social workers, and pharmacists, working collaboratively to address the various needs of patients. Each healthcare professional brings unique expertise and perspectives, contributing to a more comprehensive understanding of the patient's condition and tailoring treatment plans accordingly.
For example, a patient with a chronic...
768
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.4K